BREAST CANCER
KU Leuven
Lovaina, BélgicaPublications in collaboration with researchers from KU Leuven (6)
2024
2023
-
Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
Clinical Cancer Research, Vol. 29, Núm. 20, pp. 4068-4075
2020
-
MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum
Journal of Clinical Oncology, Vol. 38, Núm. 32, pp. 3753-3762
2017
-
Long-term follow-up of The Intergroup Exemestane Study
Journal of Clinical Oncology, Vol. 35, Núm. 22, pp. 2507-2514
2007
-
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
Lancet, Vol. 369, Núm. 9561, pp. 559-570
2004
-
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
New England Journal of Medicine, Vol. 350, Núm. 11, pp. 1081-1092